Reyataz
Gilead’s New Drug Application for Yeztugo accepted by US FDA
The investigational once-weekly oral treatment could be the first long-acting pill for HIV prevention
BMS, Macmillan and 11 NHS Trusts publish report on cancer treatment prehabilitation
The report shows how prehabilitation can improve patient experience while alleviating capacity pressures
BMS acquires Orbital Therapeutics in $1.5bn deal
The deal includes several next-gen cell therapy candidates for autoimmune diseases
BMS, Takeda and Astex join AI training consortium
The initiative focuses on training AI models to aid in drug discovery and development
Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use
An estimated 1.2 million people in the US are currently living with the virus
Gilead Sciences’ twice-yearly HIV PrEP drug Yeztugo granted FDA approval
More than 100 people in the US were diagnosed with HIV every day in 2023
BMS receives NICE recommendation for immunotherapy combination in colorectal cancer
Approximately 44,000 people are diagnosed with colorectal cancer in the UK every year
BMS receives FDA approval for immunotherapy combination in liver cancer
Around 42,240 people are expected to be diagnosed with liver cancer in the US this year
BMS granted FDA approval for immunotherapy combination in colorectal cancer
More than 154,000 cases of the disease are expected to be diagnosed in the US this year
BMS receives positive CHMP opinion for perioperative Opdivo regimen in lung cancer
Up to 55% of non-metastatic NSCLC patients will develop disease recurrence despite surgical resection
BMS granted EC approval for immunotherapy combination in liver cancer
More than 866,100 cases of the disease were diagnosed globally in 2022
Bristol Myers Squibb shares five-year results for Sotyktu in plaque psoriasis
Plaque psoriasis affects up to 90% of patients with the immune-mediated disease